Sensyne Health Partners with Bayer on New UK Artificial Intelligence ‘LifeHub’ for Data-Driven Drug Discovery, Disease Detection and Diagnosis

  • Expands on existing collaboration agreement with Bayer to accelerate the development of new treatments for cardiovascular disease using clinical AI
  • Sensyne Health will partner with Bayer on inaugural LifeHub project – developing AI enabled radiology to enhance patient outcomes

Oxford, UK; 10 October 2019: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announced it has joined Bayer’s LifeHub UK in an extension of its existing collaboration with Bayer to accelerate the development of new treatments using clinical artificial intelligence. Sensyne Health will work in partnership with Bayer on novel projects at the LifeHub UK including its inaugural project – the development of AI-enabled radiology to enhance patient outcomes.

LifeHub UK, which launches today, forms part of a global network of Bayer innovation hubs. The LifeHub UK is designed to accelerate and optimise disease detection and data-driven drug discovery by enabling Artificial Intelligence (AI)-enabled imaging solutions. Sensyne Health will be one of the first companies to have a presence in the LifeHub.

The first LifeHub UK project will focus on the development of AI-enabled radiology solutions using Sensyne Health’s proprietary clinical AI technology platform to identify digital solutions for automated image evaluation. The project will analyse research from three million anonymised, ethically sourced NHS patient records and imaging data provided through Sensyne Health’s partnerships with NHS trusts, developing digital solutions to help radiologists improve the quality of the diagnosis and increase efficiency for patients receiving the right treatment in a timely manner.

In keeping with Sensyne Health’s ethical framework and business model, the NHS remains the controller of NHS patient data, and no data is sold or transferred to a third party. Sensyne Health acts as a ‘docking station’ for the analysis of anonymised patient data on behalf of its commercial partners under strict oversight from the NHS Trusts. This ensures appropriate information governance are applied, including conformance with NHS principles, EU data protection law and applicable regulatory guidance.

In the future Sensyne Health and Bayer intend to conduct further joint R&D activities for the development of AI-enabled imaging solutions.

Lord (Paul) Drayson PhD, CEO of Sensyne Health plc, said: “Initiatives like this are essential to quickly maximise the opportunity AI presents to improve patient care and accelerate medical research. I’m delighted to be working with Bayer, extending our partnership to deliver the benefits of digital innovation directly to clinicians and patients.”

Kemal Malik, Bayer Board Member for Innovation, said: “We are delighted to launch LifeHub UK. We firmly believe that artificial intelligence has transformative potential for healthcare, leading to enhancements in prediction, prevention and personalised treatments. LifeHub UK’s roadmap is a perfect fit to Bayer’s Open Innovation strategy, which is designed to leverage places, programmes and partnerships – such as strategic alliances and joint ventures – in the life sciences fields of pharmaceuticals and agriculture.”

For more information please contact:

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer

 

Lorimer Headley, Chief Financial Officer

 
   

Peel Hunt LLP (Nominated Adviser and Broker)

+ 44 (0) 20 7418 8900

Dr Christopher Golden

 

James Steel

 

Oliver Jackson

 
   

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott

 

Sukaina Virji

 

Melissa Gardiner

 

sensynehealth@consilium-comms.com

 

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.

Back to news